R

Roche

Global pharmaceuticals and diagnostics company

Team Lead Engineering - Content Search and Knowledge Management 2

Full-Time
No salary listed
Senior
Bachelor's
Madrid, Spain
In Person
Engineering ManagementEngineering Leadership

About the job

Requirements
  • A bachelor or advanced degree in Business or an IT specialization.
  • At least 5 years of experience in people leadership, product or service management, program management, or a similar role, with a proven track record of building high-performing teams.
  • At least 2 years of experience in the pharmaceutical, biotechnology, or regulated healthcare technology industry.
  • Understanding of software development or service delivery methodologies.
  • Understanding of solution, information, and process architecture.
  • Ability to create clarity about outcomes generated by teams.
  • A lean and agile mindset.
  • Servant and creative leadership behavior.
  • A keen IT market focus and passion for major trends in the relevant discipline.
  • Executive presence, strong business acumen, and ability to navigate ambiguity and manage complexity.
  • Ability to manage risks progressively and in a way that leads to opportunity.
  • Enterprise mindset and ability to break down silos, collaborate across organizational boundaries, and bring people together toward a shared purpose.
  • Ability to empower teams and individuals to act autonomously and hold them accountable.
  • Intellectual curiosity, integrity, and a strong passion for innovation.
Responsibilities
  • Develop engineering team capabilities aligned with immediate project needs, goals, and the function’s vision.
  • Encourage team members to define their career journeys and enable development opportunities aligned with those journeys.
  • Remove roadblocks and set clear, achievable performance goals.
  • Ensure the team develops the skills and healthy dynamics needed to meet current and future challenges.
  • Maintain a sustainable team work pace while balancing delivery goals with team well-being.
  • Cultivate healthy team dynamics, collaboration, psychological safety, and open communication.
  • Remove impediments that hinder team flow or morale and act as an escalation point.
  • Ensure team members have relevant skills and clearly defined roles.
  • Co-create the product or service roadmap from a technical perspective with the Product Manager, who holds overall responsibility.
  • Be accountable for the team’s end-to-end delivery of product features in alignment with the product roadmap and quality standards.
  • Orchestrate the transition to a more mature operating model involving managed services.
  • Set clear delivery priorities aligned with product roadmaps.
  • Remove delivery impediments and escalate when needed to protect team focus.
  • Manage stakeholder expectations and needs, and provide regular updates on progress and risks.
  • Create efficiencies in collaboration across teams and functions.
  • Define success metrics, analyze workforce capability trends, and identify optimization opportunities to achieve business goals.
  • Translate data into actionable insights and communicate delivery performance regularly to stakeholders and the wider team.
  • Identify and implement process improvements within the team and in its interactions with other teams to improve efficiency and quality.
  • Support development of detailed business cases for new products or significant features.
  • Make data-driven decisions about allocating engineering, design, and other resources to maximize impact and achieve product goals.
  • Manage the team’s budget, including headcount, operational costs, and vendor contracts.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.

PR Newswire
Sep 30th, 2026
Roche launches newborn screening test for SMA, SCID and sickle cell disease

Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.

World Today News
Sep 8th, 2026
Tempus AI raises $600M to scale AI-enhanced liquid biopsy platform for cancer recurrence detection

Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.